Engineering the Therapeutics of the Future

Co-Located with Molecular Med TRI-CON Asia

May 28-31, 2013
Marina Bay Sands, Singapore

Co-Located Bio-IT World Asia


The field of engineering antibody therapeutics continues to show significant growth with an increasing number of clinical achievements being witnessed.  Antibody Engineering Asia will be held in Singapore May 28-29, 2013 and will feature keynote presentations, panels and workshops on novel methods for antibody design and engineering with special emphasis on therapeutics for cancer and autoimmune diseases.

Day 1 | Day 2 | Download Brochure 

Tuesday, May 28

7:30 Conference Registration and Morning Coffee

8:30 Conference Welcome

» Plenary Keynote Session: Molecular Medicine Asia 

9:00 New Cancer Drugs that Target Protein-Protein Interactions

David LaneSir David Lane, Ph.D., Professor & Chief Scientist, A*STAR; Director, p53 Laboratory

The search for new targets for drug discovery that has emerged from the cancer genome project has highlighted the need for novel drugs that can disrupt protein-protein interactions. Two such molecules are now in clinical trials from Roche and Abbott. Novel methods of developing such inhibitors include the development of stapled peptides and new peptidomimetics. The challenges of developing this exciting new class of medicines will be discussed with reference to the action of Mdm2 inhibitors that activate the p53 pathway and the action pro-apoptotic BH3 mimetics that induce apoptosis.

9:45 Genetic Study of Newborn Diseases with Evolving Technologies

Paul TamProfessor Paul Tam, Ph.D., Pro-Vice Chancellor and Vice President, The University of Hong Kong

10:30 Coffee Break

Antibody Engineering Rising in the East 

11:20 Chairperson's Remarks

Jaume Pons, Ph.D., Senior Vice President, Chief Technology Officer, Biotech Unit R&D Group, and CSO, Rinat

11:30 Antibodies to c-Met for Imaging and Therapy

David LaneSir David Lane, Ph.D., Professor & Chief Scientist, A*STAR; Director, p53 Laboratory

The c-Met protein is a critical cell surface receptor that is over-expressed in many forms of human cancer and is an exciting target for therapy. A new panel of antibodies we have developed has identified epitopes suitable for imaging and therapeutic targeting.

11:50 Antibody Drug Discovery Process in CPR based on Recycling & Sweeping Antibody Technology

Junichi NezuJunichi Nezu, Ph.D., Research Head, Chugai Pharmabody Research Pte. Ltd. Singapore

Chugai Pharmabody Research (CPR) is a newly established company in Singapore with a mission to develop novel antibody drug candidates based on novel antibody engineering technologies developed by its parental company, Chugai Pharmaceutical. Recycling & sweeping antibody technologies are revolutionary in the antibody drug field as they bring many advantages. These include drastic improvements to convenience for patients by reducing dosing frequency and/or by allowing subcutaneous administration, which may, in turn, lower the cost of medical for patients. Moreover, expansion of target space made possible by these technologies is crucial in terms of the future of antibody drug field.

ForteBio logo12:10 Accelerating mAb Discovery: Overcoming mAb Development Bottlenecks

Hendrick Loei, Field Application Specialist (SEA), ForteBio, A Division of Pall Life Sciences

Monoclonal antibodies (mAbs) are important tools for basic research as well as for diagnosis and therapeutic treatment of human diseases. The global market for therapeutic antibodies in 2011 was estimated at approximately $45 billion, and is expected to hit $60 billion by 2016. The increasing demand for better quality antibodies with better specificities have pushed innovators to come up with improved methods for discovery and screening of antibody libraries. In this presentation, we will discuss how Pall-Fortebio’s high-throughput label-free technologies have accelerated mAb development in areas such as titer determination, clone selection, library screening for high-affinity antibodies and epitope binning.

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

14:00 Chairperson's Remarks

Stephen MahlerStephen Mahler, Ph.D., Professor, Head of Discipline Chemical and Biological Engineering, Australian Institute for Bioengineering and Nanotechnology

14:10 Engineered Antibody Constant Domains (Nanoantibodies): Implications for Development of Novel Candidate Therapeutics

Rui GongRui Gong, Ph.D., Professor, Head, Antibody Engineering Group, Wuhan Institute of Virology, Chinese Academy of Sciences, China

Identification of a binder from a CH2-based library that targets HIV-1 envelope and maintains pH-dependent neonatal Fc receptor binding provides a proof-of-concept that CH2-based antigen binders (nanoantibodies) that also mimic certain extent other functions of full-size antibodies represent novel candidate therapeutics.

14:30 Antibody Engineering to Address Novel Biological Questions

Jaume Pons, Ph.D., Senior Vice President, Chief Technology Officer, Biotech Unit R&D Group, and CSO, Rinat

We have devised novel technologies that address pH sensitive binding to extend PK, bispecific antibody generation and antibody-drug conjugation to address novel biological questions. These include: 1. What is the role of site of conjugation to pharmacokinetics, safety, and efficacy? 2. What is the best way to engage effector cells using a bispecific construct? and 3. What is the best way to reduce target mediated degradation of therapeutic antibody?

14:50 Q&A

15:00 Refreshment Break

15:30 Antibody Therapeutics Developments and Market Opportunities in Japan

Satoshi BanbaSatoshi Banba, Executive Director, Medical & BioTechnology Department, Seed Planning, Inc.

Japan is the biggest antibody therapeutics market in Asia, and there are a lot of companies which are engaged in antibody therapeutics development. At this conference, I will give a lecture on current and future antibody market/developments in Japan.

Engineering for Therapeutic Targets 

15:50 Using StaRs to Generate Therapeutic Antibodies to GPCR Targets

Catherine HutchingsCatherine Hutchings, Ph.D., Principal Scientist, Antibody Discovery & Strategy Partnering, Heptares Therapeutics Ltd.

The opportunity for targeting GPCRs with antibodies will be outlined, with the challenges encountered and examples of therapeutic GPCR antibodies currently in clinical development described. Here we present a novel approach using Stabilized Receptors (StaRs), where GPCRs have been engineered to include a small number of point mutations that greatly increases the stability of the receptors. Data will be presented that exemplify approaches to demonstrate the potential of StaRs to generate therapeutic antibodies.

16:10 Engineered Antibody Domains and Multispecific Fusion Proteins as Candidate Therapeutics against Cancer and HIV-1

Dimiter DimitrovDimiter Dimitrov, Ph.D., Senior Investigator, Center for Cancer Research, National Cancer Institute, NIH

We developed large libraries of engineered antibody domains from which binders against cancer-related proteins and HIV-1 envelope glycoproteins were selected and characterized. Bispecific antibodies and multispecific fusion proteins were engineered targeting cancer related proteins and HIV-1. The bispecific antibodies could have potential as cancer therapeutics. The multispecific fusion proteins conjugated with small molecule toxins could be used for HIV-1 eradication.

16:30 Therapeutic Mirror Proteins for Eye and Lung Diseases

Dana Ault-Riche, Ph.D., CEO, Pharmaceuticals, Reflexion Pharmaceuticals

Mirror proteins are small proteins made entirely of D-amino acids. They are resistant to proteolysis and are non-immunogenic, giving them near ideal properties as therapeutic molecules. This presentation will discuss recent advances in developing mirror proteins for the treatment of macular degeneration, diabetic macular edema, influenza and LAM.

16:50 Empowered Antibody-Fusion Proteins to Effectively Treat Cancer

Sanjay Khare, Ph.D., CEO and President, ImmunGene, Inc.

Empowered antibody-fusion proteins are engineered to overcome safety challenges of potent anti-tumor cytokines to target hematological and solid cancer. Preclinical efficacy and safety data will be discussed. This approach offers advantages efficacy/safety profile, small convenient dosing, as well as ease of manufacturing.

17:10 Q&A with Speakers

17:30 Welcome Reception in the Exhibit Hall with Poster Viewing

18:30 Close of Day

Day 1 | Day 2 | Download Brochure